Description
The global single-use bioprocessing market was valued at USD 13.8 billion in 2028 and is projected to reach USD 27 billion by 2032, registering a CAGR of 10.1% during the forecast period. Single-use bioprocessing (SUB) technologies comprise disposable bioreactors, bags, mixers, filtration assemblies, tubing, connectors, sensors, and sampling systems that replace conventional stainless-steel equipment in biologics manufacturing. These systems minimize cross-contamination risks, eliminate cleaning validation requirements, reduce water and energy consumption, and enable rapid production changeovers, making them increasingly essential for the manufacturing of monoclonal antibodies, vaccines, recombinant proteins, biosimilars, and advanced cell and gene therapies. Growing demand for biologics, expanding biopharmaceutical production capacity, and increasing adoption of flexible manufacturing platforms are the primary factors driving market growth.
Market expansion is further supported by rising investments in contract development and manufacturing organizations (CDMOs), rapid commercialization of cell and gene therapies, and continuous technological advancements in disposable bioprocessing systems. Single-use technologies provide manufacturers with improved scalability, lower capital expenditure, faster facility deployment, and enhanced operational flexibility. Increasing adoption of continuous bioprocessing, automation, digital process monitoring, and Industry 4.0 technologies is further transforming biologics manufacturing workflows. North America currently dominates the global market owing to its strong biopharmaceutical manufacturing base and advanced biotechnology infrastructure, while Asia Pacific is expected to register the fastest growth due to increasing investments in biologics manufacturing, expanding CDMO operations, and supportive government initiatives.
Key Highlights of the Report
• By product, simple & peripheral elements dominate the global single-use bioprocessing market, accounting for the largest market share due to extensive adoption of bags, tubing, connectors, filters, and sampling systems throughout biomanufacturing workflows.
• Bioreactors and mixers are projected to witness significant growth, supported by increasing demand for flexible upstream processing and commercial biologics manufacturing.
• By workflow, upstream processing accounts for the largest market share, driven by increasing utilization of disposable bioreactors, media preparation systems, and cell culture technologies for biologics production.
• Downstream processing is expected to register the fastest growth, owing to increasing adoption of disposable filtration systems, chromatography assemblies, and purification technologies.
• By application, monoclonal antibody production dominates the global market, reflecting the expanding global pipeline and commercialization of biologic therapeutics.
• Cell and gene therapy manufacturing is projected to witness the fastest growth, driven by increasing clinical approvals, personalized medicine, and demand for flexible small-batch manufacturing platforms.
• By end use, biopharmaceutical manufacturers account for the largest market share, supported by continuous expansion of biologics production facilities and increasing investment in manufacturing modernization.
• Contract development and manufacturing organizations (CDMOs) are expected to witness substantial growth, driven by rising outsourcing of biologics development and commercial manufacturing.
• Growing demand for biologics and biosimilars remains one of the primary market drivers, encouraging pharmaceutical companies to adopt flexible, scalable, and contamination-free manufacturing technologies.
• Single-use technologies significantly reduce cleaning validation requirements, capital expenditure, water consumption, and turnaround time, improving manufacturing efficiency and accelerating product commercialization.
• Technological advancements in disposable sensors, automated monitoring systems, and digital bioprocess control platforms are improving manufacturing performance, enabling real-time monitoring and enhanced process reliability.
• Increasing investments in vaccine manufacturing, mRNA platforms, and advanced therapy medicinal products (ATMPs) continue to create strong growth opportunities for single-use bioprocessing equipment suppliers.
• By region, North America dominates the global single-use bioprocessing market, supported by advanced biotechnology infrastructure, robust pharmaceutical R&D activities, and strong adoption of disposable manufacturing technologies.
• Asia Pacific is projected to witness the fastest growth, driven by rapid expansion of biologics manufacturing facilities, increasing government support for biotechnology, and growing investments from global pharmaceutical companies.
• The competitive landscape is highly competitive, with leading companies focusing on next-generation disposable technologies, integrated bioprocessing platforms, strategic partnerships, and manufacturing capacity expansion to strengthen their global presence.
• Major manufacturers continue investing in advanced single-use bioreactors, filtration systems, sensors, and automation technologies, addressing the growing demand for efficient, scalable, and contamination-free biologics manufacturing.
Key Company Profiles
• Avantor Inc.
• Cellexus International Ltd.
• Celltainer Biotech BV
• Danaher Corporation
• Entegris Inc.
• Meissner Filtration Products Inc.
• Parker Hannifin Corporation
• Repligen Corporation
• Saint-Gobain Life Sciences
• Thermo Fisher Scientific Inc.
Data Source
Apelo Consulting employs comprehensive primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by Apelo Consulting dedicated team of qualified professionals with deep industry experience and expertise.
